Prøve GULL - Gratis

Hotspots & growth opportunities in biomanufacturing

Chronicle Pharmabiz

|

November 27, 2025

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

- Vandana Iyer

The country has also witnessed an exponential rise in biotech startups in the past decade, as shown in Figure 1 below: India witnessed an almost 200-fold increase in biotech startups in the past 10 years.

The launch of Government of India policies such as BIRAC funding schemes (BIG (Biotechnology Ignition Grant), SEED (Sustainable Entrepreneurship and Enterprise Development) and LEAP (Launching Entrepreneurs for Affordable Products), the BioE3 Policy (India's "Biotechnology for Economy, Environment, and Employment" policy) and e-platforms such as Startup India have significantly accelerated the growth of the innovation ecosystems for Indian biotech post-2017.

imageAs shown in Figure 2, Karnataka, Tamil Nadu and Maharashtra are the leading biotech hubs in Indial. In September 2025, the Government of India launched High Performance Biomanufacturing Platforms, a joint initiative of the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC).

This newly launched network comprising advanced biofoundries and biomanufacturing hubs will use tools such as synthetic biology, omics technologies, artificial intelligence, machine learning to advance developments across the Indian biotech, healthcare, agriculture, energy, climate, and food industries.

imageIndia already has over 21 biofoundries, compared to a global hub of 100, which positions India as an important innovation hotspot in global biomanufacturing space.

Key drivers and challenges impacting Indian biomanufacturing sector

The Indian Government is currently focused on six thematic sectors for driving biomanufacturing growth, which are shown below:

FLERE HISTORIER FRA Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size